Marshall Wace
RVPH

Marshall Wace’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Marshall Wace’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,825
Closed -$206K – 3097
2025
Q1 		$206K Buy
+10,825
New +$340K ﹤0.01% 2395
2024
Q2 		– Sell
-1,743
Closed -$132K – 2898
2024
Q1 		$132K Sell
1,743
-212
-11% -$16.8K ﹤0.01% 2280
2023
Q4 		$201K Buy
+1,955
New +$175K ﹤0.01% 1977

Other funds holding RVPH

DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Marshall Wace's RVPH Position: Q2 2025 in Review

Marshall Wace sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2025, closing a stake of 10,825 shares — an estimated $206K sold.

Marshall Wace first reported a position in RVPH in Q4 2023 and held it in 3 quarters. The position peaked at $206K in Q1 2025. 46 funds tracked by Wall St. Rank hold RVPH as of Q2 2025.

  • Marshall Wace reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2025 after selling out during the quarter.
  • Marshall Wace sold 10,825 REVIVA PHARMA HLDGS INC shares in Q2 2025, an estimated $206K.
  • Marshall Wace first reported a position in REVIVA PHARMA HLDGS INC in Q4 2023 and held it in 3 quarters.
  • Marshall Wace's REVIVA PHARMA HLDGS INC position peaked at $206K in Q1 2025.
  • 46 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.